Skip to main content
. 2021 Feb 9;22(4):1737. doi: 10.3390/ijms22041737

Figure 6.

Figure 6

Mechanism of antiviral drugs inhibition of SARS-CoV-2. Chloroquine and hydroxychloroquine raise endosomal pH and block viral uncoating. Additionally, they seem to interrupt glycosylation of the spike protein, which is expected to block SARS-CoV-2 recognition of ACE2. However, recent clinical trials did not show any benefits, i.e., decreased mortality or short recovery time. Thus, the FDA recommended clinicians not use chloroquine or hydroxychloroquine for patients. Remdesivir is a nucleotide analogue that blocks the activity of RNA-dependent RNA polymerase (RdRP). Additionally, clinical trials showed that the use of remdesivir shortened the recovery time of COVID-19 patients.